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Background/aim: In this prospective randomized cross-over study we compare the effects of sevoflurane versus propofol for
electroconvulsive therapy (ECT) anesthesia.
Materials and methods: Twenty four patients (ASA I–III, 18–65 years old) receiving ECT three times per week were included.
Anesthesia was induced with either propofol (0.75 mg/kg iv) or 5% sevoflurane in 100% oxygen. Consecutive ECT sessions followed a
2 × 2 crossover design and a 2-day washout period until the 10th ECT. Intravenous succinylcholine (1 mg/kg) was administered while
bispectral index (BIS) values were ≤60%.
Results: Electromyogram and electroencephalogram seizure duration, postictal suppression index, BIS values, mean arterial blood
pressure (MAP), heart rate, times to start of spontaneous respiration, eye opening, understanding verbal commands, and side effects
were compared. No differences were found between the regimens for seizure activity and recovery. At the end of ECT, MAP was higher
with sevoflurane. Although BIS values were higher after sevoflurane, no differences between the regimens were found in terms of the
need of muscle relaxants and in hypnosis levels.
Conclusion: Sevoflurane (5%) may be an effective alternative to propofol for induction of anesthesia for ECT.
Key words: Electroconvulsive therapy, anesthesia, propofol, sevoflurane, bispectral index

1. Introduction
Electroconvulsive therapy (ECT) is the preferred treatment
for affective disorders, and especially major depression,
schizophrenia, and other psychotic disorders that do
not respond well to psychopharmacological treatment,
when pharmacologic treatment is not well tolerated or
in situations when a fast clinical response is required.
Despite disagreements on the relationship between the
effectiveness of ECT treatment and seizure duration, the
suggested time for clinical effectiveness is 25–30 s (1,2).
Moreover, electroencephalogram (EEG) signs of intense
seizure with high amplitude and postictal EEG suppression
are reported to be indicative of the efficacy of treatment
(1–5). The postictal suppression index (PSI) reports on the
* Correspondence: aysunposta@yahoo.com
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degree of EEG flattening at the end of seizure and indicates
ECT seizure quality. The PSI is also reported to correlate
with clinical efficacy (3,5,6).
Agents used to induce anesthesia for ECT should
provide rapid induction and recovery, have few side effects,
and not reduce the effectiveness of ECT. However, no
anesthetic agent is known to provide all these requirements.
A sensitive balance is required between providing optimal
seizure duration and achieving a sufficient depth of
anesthesia (1). Whereas high-dose anesthetic agents might
reduce the effectiveness of ECT, low-dose agents may not
provide an adequate depth of anesthesia and may also
negatively affect the progress of the psychiatric disease
(7,8). Direct measurement of the individual hypnosis level
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is reported to help in determining the anesthetic dosage
and ECT application time, as well as reducing awareness
(9,10). The bispectral index (BIS) is an EEG-derived scale
reflecting the level of hypnosis and an important parameter
in anesthesia for ECT (9–11).
Inhalational induction for ECT is preferred for patients
with needle phobia, agitation, (known) problems related
to inserting an intravenous (IV) line, and for patients with
(expected) difficult airway management (12). Sevoflurane
is an inhalation anesthetic that provides fast and smooth
induction, has a quick elimination, and does not irritate
the airways (13). It is also preferred in the last trimester of
pregnancy for ECT anesthesia because it reduces uterine
contractions (14). Although studies have compared
induction with sevoflurane and IV anesthetic agents, there
is no consensus on the effects of sevoflurane on seizure
duration (12,15–18). It is emphasized that the depth of
anesthesia should be determined during induction of
anesthesia for ECT (18,19).
In the present study the level of hypnosis was monitored
using BIS. The aim was to compare hemodynamic
responses, BIS scores, seizure parameters, and recovery
profiles for sevoflurane and propofol for induction of
anesthesia for ECT.
2. Materials and methods
2.1. Overview
This single-center, single blind, randomized, prospective,
crossover exploratory study was performed at Numune
Educational and Research Hospital (Ankara). The study
was approved by the local Institutional Ethics Committee
(2007-08884).
A total of 27 patients (aged between 18 and 65 years)
receiving ECT three times a week (to complete an average
of 10–12 treatments) were enrolled in the study (between
2007 and 2009). Patients with mask phobia, epilepsy,
unstable cardiovascular disease, sinus bradycardia, second
or third degree atrioventricular block, cerebrovascular
disease, chronic obstructive pulmonary disease, hepatic
or renal insufficiency, organic brain disease, current
alcohol use or other substance dependence, and patients
receiving treatment with beta blockers, anticonvulsants, or
benzodiazepines were excluded from the study.
After the patients (or their relatives) were informed
about the study and signed consent forms, patients were
examined and classified as ASA physical status I–III prior
to ECT treatment. During the study, the following patients
were also excluded from the analysis: patients who could
no longer tolerate mask induction, those who had a very
high level of trigger points, patients who had a seizure
duration ≥120 s, and patients whose treatments were
completed earlier than planned (<8 ECT sessions).

2.2. Study design
Patients were randomized (using the sealed envelope
method) to either IV propofol (0.75 mg/kg) or sevoflurane
(5%). This study was performed using a 2 × 2 crossover
design with a 2-day washout period until the 8th ECT
session, at which point the study ended. Electrical
stimulus trigger points were determined during the first
two ECT sessions; these two sessions were not included in
the present analysis, and in these sessions propofol and IV
remifentanil were used for induction of anesthesia.
2.3. Procedure and data collection
Patients were brought to the ECT room without any
premedication and were administered Ringer’s lactate
infusion after insertion of an IV line in their forearm.
Electrocardiogram (ECG), noninvasive blood pressure,
heart rate (HR), peripheral oxygen saturation (SpO2), endtidal carbon dioxide (Datex Ohmeda S/5, Bromma), and
BIS (BIS XP, Aspect Medical System) were monitored.
Hemodynamic data were recorded before induction, after
induction, immediately at the end of ECT (ECT-E), and
at 1 and 5 min after the end of ECT (ECT + 1 and ECT
+ 5, respectively). BIS values were recorded before and
after induction, before administration of muscle relaxants,
immediately before ECT (preictal) and 5 min following
ECT (postictal).
ECT was applied bilaterally using the Thymatron
TM DGx device (Somatics LLC). EEG electrodes were
placed on the frontal and mastoid protuberances by the
psychiatrist and the electromyogram (EMG) electrodes
were placed on the flexor side of the right forearm. Seizure
quality was determined using the PSI, which is calculated
by the Thymatron device. All patients were preoxygenated
with 4 L/min 100% O2 for 3 min using a face mask;
additionally, 1 min before induction IV remifentanil
1 µg/kg was administered over 30–45 s (in our clinic
remifentanil is used routinely to reduce the dosage of the
induction agent and to suppress hemodynamic response).
For the first treatment, patients received ECT at 30%–
50% of the maximum output stimulus, depending on
the attending psychiatrist’s decision. After the first ECT
session, the same psychiatrist decided on the stimulus
amplitudes according to the patient’s clinical outcome.
In the propofol regimen, propofol 0.75 mg/kg was
administered IV over
30–45 s. Patients were clinically assessed approximately
60 s after propofol administration and additional propofol
was given in 10–20 mg increments as needed until loss of
eyelash reflex and loss of response to verbal commands.
The total propofol dosage was recorded.
In the sevoflurane regimen, the respiratory circuit was
primed for 60 s using sevoflurane 5% in 100% O2 with a
4 L/min gas flow. Patients were asked to breathe through
the face mask connected to the system (tidal volume
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breathing) and the vaporizer was turned off after induction.
Sufficient depth of anesthesia was determined by loss of
consciousness, loss of eyelash reflex, and unresponsiveness
to the verbal order of “open your eyes”; this was recorded
as the induction time. When the BIS value was ≤60,
succinylcholine 1 mg/kg (IV bolus) was administered
and the times of administration of muscle relaxants were
recorded. Ventilation was maintained with a face mask at 4
L/min O2 and the end-tidal CO2 was maintained at 32–35
mmHg. Induction of anesthesia was performed with the
alternative agent in each consecutive application of ECT
(as described above).
Two observers (a psychiatrist and an anesthesiologist)
who were not informed about the type of induction were
brought into the ECT room before each application
of ECT. The EEG and EMG seizure duration, as well as
the PSI score, were recorded at the end of the seizure.
Times from induction to the beginning of spontaneous
respiration, eye opening, and understanding of verbal
commands were recorded. Furthermore, adverse side
effects such as agitation, nausea, and vomiting, secretion,
atrial and ventricular arrhythmias, and bradycardia (HR
≤ 45 beats/min) were recorded. Patients were brought
to the recovery room when their modified Aldrete score
was ≥9. When the patient was about to leave the recovery
room to return to their room, any changes in ECG and/
or complications were noted. Then, they were returned to
their room when they were able to get off the stretcher and
sit on the wheelchair by themselves. During the following
24 h patients were asked about nausea and vomiting, and
what they remembered about the ECT sessions.
2.4. Statistical analysis
Baseline characteristics are summarized using number of
patients, mean and standard deviation (SD) for continuous
data, and number and percentage of patients for categorical
data. To investigate any potential imbalance over the
two study arms on baseline characteristics, Wilcoxon
sum-rank and chi-square tests were used for continuous
and categorical subject characteristics, respectively.
Additionally, summary statistics were obtained for the
outcome parameters at each time point.
One sample Kolmogorov–Smirnov test was used to
search the normal distribution of the variables in this
study and it was determined that the variables fit the
normal distribution.
Outcome variables were analyzed based on the mixed
model framework by considering appropriate model
structure (fixed effects: sequence, period, and treatment;
random effect: intercept and time, with patients nested
within sequence). Results are tabulated according to
changes from baseline estimates for each study outcome.
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The significance level was set at P ≤ 0.05; all analyses
were performed with the open source statistical software
package R for Windows. The sample size of the study was
determined on the basis of the samples sizes of the previous
studies (12,17). The results of this analysis demonstrated
a power of 97.9% for two regimens with n = 72 in each
group [s (SD):17.84, Δ: –8.58, 2 tailed-α: 0.05 ].
3. Results
Of the 27 patients enrolled in the study, 17 were diagnosed
with depression (of whom 10 had a high risk of suicide
and 7 refused oral treatment) and 10 were diagnosed
with schizophrenia. All patients were incompatible with
oral treatment and had intense psychomotor agitation.
Nine of the patients diagnosed with depression had
bipolar depressive episodes and the remainder had major
depression with psychosis. Of the 27 patients, 2 were
withdrawn from the study due to their high threshold
values, and 1 patient was withdrawn because he refused
the use of a face mask. Therefore, data of 24 patients
(with 3–8 ECT sessions) were used for the analyses; the
characteristics of these patients are presented in Table 1.
3.1. Seizure parameters
There were no significant differences between the two
regimens in terms of induction time, PSI, the energy
needed to generate a seizure, and the EMG and EEG
seizure duration (Table 2). During a total of 144 ECT
applications, mean EMG seizure duration was ≤25 s in 30
patients receiving propofol and in 32 patients receiving
sevoflurane (P > 0.05).
3.2. BIS variables
Immediately after induction, BIS values were higher in the
sevoflurane group compared with the propofol group (P
= 0.000, Table 2). The times of administration of muscle
relaxants were significantly longer with sevoflurane (Table
2). No other significant differences were found between
the two regimens in terms of BIS values obtained during
administration of muscle relaxants.
3.3. Hemodynamic variables
Data on hemodynamic variables are presented in Table
3. After induction, there was a similar decrease in MAP
in both regimens. However, HR was significantly lower
with sevoflurane than with propofol treatment (P = 0.001).
At 1 min after ECT, MAP was significantly higher with
sevoflurane than with propofol treatment (P = 0.048).
3.4. Recovery parameters
There were no significant differences between the two
regimens for the time of starting spontaneous respiration,
eye opening, and response to verbal commands (Table
3). There was also no difference between the regimens
regarding adverse side effects (Table 4).
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Table 1. Characteristics of the study population.
Total number of patients

24

Total number of ECT treatments

144

Mean age in years (range)

38.08 ± 10.06 (20–57)

Mean weight (kg)

69.35 ± 13.38

Gender (male/female)

16/8

Median ASA (range)

2 (1–3)

Indication:
depression

15

schizophrenia

9

Initial dose of propofol (mg/kg)

0.75

Total dose of propofol (mg/kg)

0.89 ± 0.01

Sevoflurane

5%

Data are presented as means ± standard deviation (SD).

Table 2. Data on seizure outcome and bispectral index (BIS) scores during ECT.
Propofol
Mean ± SD

Sevoflurane
Mean ± SD

P-value

176.92 ± 9.50

178.46 ± 9.01

0.8558

Induction time (s)

69.2 ± 32.3

73.1 ± 40.8

0.480

MRAT (s)

66.1 ± 19.2

89.0 ± 22.7

0.004*

EMG seizure duration (s)

27.5 ± 12.4

29.82 ± 13.6

0.469

EEG seizure duration (s)

41.83 ± 19.8

43.23 ± 32.5

0.832

PSI scores (%)

70.1 ± 23.1

67.5 ± 23.8

0.455

Before induction of anesthesia

94.0 ± 3.2

94.78 ± 3.5

0.923

After induction of anesthesia

58.9 ± 15

71.1 ± 17.3

0.000**

Before muscle relaxant

50.0 ± 9.5

55.8 ± 13.1

0.092

Preictal

45.0 ± 10

42.5 ± 13.3

0.129

Postictal

72.5 ± 13.9

69.9 ± 17.5

0.380

Applied energy (mc)

Bispectral index (%)

Data are presented as means and standard deviation (SD).
MRAT: muscle relaxant administration time; PSI: postictal suppression index.
*: P = 0.004 significantly different from the other regimen. **: P = 0.000 significantly different from the other regimen.
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Table 3. Hemodynamic data and recovery times during ECT.
Propofol
Mean ± SD

Sevoflurane
Mean ± SD

before induction of anesthesia

86 ± 13.5

85.4 ± 12.6

0.592

ater induction of anesthesia

80.8 ± 17.3

74.8 ± 16

0.001*

ECT + E

132.2 ± 22.5

131.1 ± 18.4

0.808

ECT + 1

100.1 ± 17.7

96.4 ± 19.2

0.080

ECT + 5

105.1 ± 17.4

105.6 ± 14.8

0.990

before induction of anesthesia

87.1 ± 12.1

87.3 ± 13.3

0.901

after induction of anesthesia

72.3 ± 13.3

74.1 ± 13.7

0.353

108.1 ± 23.6

0.051
0.048**

P-value

Heart rate (bpm)

Mean arterial pressure (mmHg)

ECT + E

102.5 ± 21

ECT + 1

99.8 ± 21.0

108.4 ± 23.1

ECT + 5

94.1 ± 14.3

93.4 ± 14.8

0.747

Spontaneous respiration

7.14

± 1.6

7.31

± 1.7

0.354

Eye opening

10.43 ± 2.6

11.05

± 3.29

0.074

Following verbal commands

14.63 ± 5.6

14.80

± 5.2

0.803

Recovery time (min)

Data are presented as means and standard deviation (SD).
ECT: Electroconvulsive therapy; ECT + E: End of ECT; ECT + 1: 1 min after end of ECT; ECT + 5: 5 min after end
of ECT; *: P = 0.001 significantly different from the other regimen. **: P = 0.048 significantly different from the other
regimen.
Table 4. Adverse side effects reported after induction with the two regimens.
Propofol
(n=72 ECT applications)

Sevoflurane
(n = 72 ECT applications)

P-value

Agitation

13

20

0.108

Nausea/vomiting

3

5

0.414

Secretion

4

2

0.157

Atrial arrhythmia

7

7

1.000

Ventricular arrhythmia

3

4

0.650

Bradycardia

0

1

0.157

4. Discussion
The present study is the first to compare induction
with sevoflurane and with propofol for ECT using BIS
monitoring to determine the level of hypnosis. No
significant differences were found between the two
regimens regarding seizure parameters, recovery profiles,
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and BIS variables. For hemodynamic variables, only MAP
at the end of ECT was significantly higher with sevoflurane
than with propofol treatment; there were no differences
between the two regimens at any other time points. In
the present study, mean seizure times were within the
suggested range (1,2).
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Propofol is preferred for ECT since it provides
hemodynamic stability and a comfortable recovery
(1,20,21). However, propofol is reported to reduce seizure
duration induced by ECT in a dose-dependent manner
(19–22). Addition of remifentanil to the induction agent
increases seizure time by decreasing the required dose
of the anesthetic agent, suppresses the hemodynamic
response induced by ECT, and increases the PSI score
(22–25). Akcaboy et al. (23) demonstrated that addition
of remifentanil (1 µg/kg) to propofol (0.5 mg/kg) increases
seizure duration as compared with propofol alone (0.75
mg/kg) (with motor seizure times of 52.2 s and 37.6 s,
respectively). For this reason, in our clinic remifentanil is
routinely used in ECT induction.
The first study to use sevoflurane as an inhaled
anesthetic for ECT anesthesia was performed by Calarge et
al. (17); they compared sevoflurane (8% for induction and
2%–4% for anesthesia maintenance) with methohexital in
12 patients (69 treatments) and found that motor seizure
time was shorter in sevoflurane treatment. In a total of 56
treatments, Loughnan et al. (12) compared 8% sevoflurane
(continued until just before electrical stimuli starts) with
1–1.5 mg/kg propofol and reported that motor seizure time
was longer in the sevoflurane group than in the propofol
group, but the seizure time was still shorter than the
accepted seizure time (the mean time for propofol was 18.5
s vs. 22 s for sevoflurane); while there was no significant
difference between the two treatments for EEG seizure
times, they reported higher PSI levels in the propofol
regimen (with a median of 90.5%) than in the sevoflurane
regimen (with a median of 87%). Wajima et al. (18) also
compared sevoflurane (induction and maintenance at 5%)
to propofol (1.5 mg/kg); they reported that motor seizure
time was shorter in the sevoflurane group (with a median
of 16 s) than in the propofol group (with a median of
30 s). In another study, Toprak et al. (15) compared 7%
sevoflurane (which was ended after induction) with 1.5
mg/kg propofol and found that motor seizure time was
significantly higher in the sevoflurane group than in the
propofol group (mean time for propofol was 28.91 s, while
for sevoflurane it was 43.04 s). Our results for motor and
EEG seizure times do not concur with those reported by
Loughnan et al. (12) and Toprak et al. (15). Avramov et
al. (21) demonstrated that propofol in doses of ≥1 mg/kg
caused a 45% decrease in ECT-induced seizure duration.
The differences between our results and those of the other
groups (i.e. Loughnan et al. (12), Toprak et al. (15), and
Wajima et al. (18)) might be due to the amount of propofol
used. For example, we used a mean of 0.89 mg/kg propofol,
which is lower than the amounts used by the other groups.
The reason why Calarge et al. (17) and Wajima et al. (18)
found a shorter duration of seizure in the sevoflurane

regimen might be because, in their protocols, both groups
continued sevoflurane administration after induction. In
the study by Wajima et al. (18), the patient population was
older (mean age 57 years) than ours, which might imply
the need to apply a relatively higher concentration of
sevoflurane.
Even after a fixed dose of an anesthetic agent for ECT
anesthesia, the hypnosis level is not the same for all patients
due to pharmacokinetic differences among individuals (4).
However, individual pharmacokinetic differences are dealt
with by objective monitoring of the depth of hypnosis. This
allows administration of an optimal anesthetic dosage,
avoiding an inadequate anesthesia level or too heavy a
sedation (4,7).
In the present study, before ECT the BIS values were
within a range to prevent awareness and were similar in
both groups; however, BIS values obtained after anesthesia
induction showed a significant difference between the
two regimens. During administration of muscle relaxants,
this difference disappeared and a satisfactory depth of
anesthesia was achieved. We think that the significant
difference in BIS values between the two regimens after
induction might be because induction with sevoflurane
takes longer compared with induction with propofol. It is
reported that changes in seizure duration depend on dosage
and on whether sevoflurane is used in the maintenance of
anesthesia (12,15,17). In the present study, we think that
the differences in mean seizure duration were due to how
sevoflurane was administered and the concentration used.
A retrospective study by Porter et al. (25) demonstrated
that addition of remifentanil to propofol induction
provided higher PSI values. A higher PSI value is reported
to be an indicator of more clinical improvement (3,5,6). In
contrast to Loughnan et al. (12), who found that the PSI
values with sevoflurane were better than with propofol, we
found no significant difference in PSI values between the
two regimens. Moreover, we found that both anesthetic
agents were similar in terms of effectiveness for ECT.
A typical response in ECT after electrical stimulation
is an increase in the parasympathetic response (for 10–15
s) followed by a sympathetic response. Hypertension,
tachycardia, and ventricular extrasystole are often
observed during the sympathetic response (1,18). It is
also reported that hemodynamic responses are suppressed
when using opioid analgesics in ECT (22,23). Recart et
al. (24) evaluated hemodynamic responses and seizure
duration in ECT using three doses of remifentanil (25, 50,
100 µg, or saline) in addition to 1 mg/kg methohexital;
they found that 100 µg of remifentanil suppressed acute
hemodynamic responses without affecting seizure
duration and recovery. In our study, immediately after
ECT application, MAP increased in both regimens (but
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slightly more with sevoflurane than with propofol) and 5
min after ECT cessation the values returned to baseline
levels. Although not clinically important, a larger increase
in MAP and HR in the sevoflurane group was previously
reported (12,15,18). In our study remifentanil was effective
in providing hemodynamic stability.
The effectiveness of ECT was not investigated in the
current study. Another limitation is the presence of
sevoflurane odor after induction; although our observers
were blinded to the regimen applied, the odor of this agent
lingered on.

Although induction with sevoflurane for ECT is not
yet common practice, when indicated, it can be used at
a 5% concentration together with BIS monitoring, which
provides valuable information about the hypnosis level.
We think that sevoflurane can be as effective for seizure
outcomes as propofol and that it may be an effective
alternative to propofol in ECT practice.
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